Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort

Genetic polymorphisms have been associated with risk of antituberculosis treatment toxicity. We characterized associations with adverse events and treatment failure/recurrence among adults treated for tuberculosis in Brazil. Participants were followed in Regional Prospective Observational Research i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacogenetics and genomics Ročník 35; číslo 2; s. 55
Hlavní autoři: Amorim, Gustavo, Jaworski, James, Yang, Jing, Cordeiro-Santos, Marcelo, Kritski, Afrânio L, Figueiredo, Marina C, Turner, Megan, Andrade, Bruno B, Velez Edwards, Digna R, Santos, Adalberto R, Rolla, Valeria C, Sterling, Timothy R, Haas, David W
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.02.2025
Témata:
Adult
Antitubercular Agents - adverse effects
Antitubercular Agents - therapeutic use
Arylamine N-Acetyltransferase - genetics
Brazil
Cohort Studies
Female
Glutathione Transferase - genetics
Humans
Liver-Specific Organic Anion Transporter 1
Male
Middle Aged
Pharmacogenetics
Polymorphism, Single Nucleotide
Pregnane X Receptor
Prospective Studies
Treatment Outcome
Tuberculosis - drug therapy
Tuberculosis - genetics
Tuberculosis, Pulmonary - drug therapy
Tuberculosis, Pulmonary - genetics
Brazil
ISSN:1744-6880, 1744-6880
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Genetic polymorphisms have been associated with risk of antituberculosis treatment toxicity. We characterized associations with adverse events and treatment failure/recurrence among adults treated for tuberculosis in Brazil. Participants were followed in Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil. We included persons with culture-confirmed drug-susceptible pulmonary tuberculosis who started treatment between 2015 and 2019, and who were eligible for pharmacogenetics. Treatment included 2 months of isoniazid, rifampin or rifabutin, pyrazinamide, and ethambutol, then 4 months of isoniazid and rifampin or rifabutin, with 24-month follow-up. Analyses included 43 polymorphisms in 20 genes related to antituberculosis drug hepatotoxicity or pharmacokinetics. Whole exome sequencing was done in a case-control toxicity subset. Among 903 participants in multivariable genetic association analyses, NAT2 slow acetylator status was associated with increased risk of treatment-related grade 2 or greater adverse events, including hepatotoxicity. Treatment failure/recurrence was more likely among NAT2 rapid acetylators, but not statistically significant at the 5% level. A GSTM1 polymorphism (rs412543) was associated with increased risk of treatment-related adverse events, including hepatotoxicity. SLCO1B1 polymorphisms were associated with increased risk of treatment-related hepatoxicity and treatment failure/recurrence. Polymorphisms in NR1/2 were associated with decreased risk of adverse events and increased risk of failure/recurrence. In whole exome sequencing, hepatotoxicity was associated with a polymorphism in VTI1A , and the genes METTL17 and PRSS57 , but none achieved genome-wide significance. In a clinical cohort representing three regions of Brazil, NAT2 acetylator status was associated with risk for treatment-related adverse events. Additional significant polymorphisms merit investigation in larger study populations, particularly regarding risk of treatment failure/recurrence.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1744-6880
1744-6880
DOI:10.1097/FPC.0000000000000552